Published ahead of print on July 15, 2004, doi:10.1164/rccm.200401-033OC
American Journal of Respiratory and Critical Care Medicine Vol 170. pp. 836-844, (2004)
© 2004 American Thoracic Society
doi: 10.1164/rccm.200401-033OC
Can Guideline-defined Asthma Control Be Achieved?
The Gaining Optimal Asthma ControL Study
Eric D. Bateman,
Homer A. Boushey,
Jean Bousquet,
William W. Busse,
Tim J. H. Clark,
Romain A. Pauwels and
Søren E. Pedersen for the GOAL Investigators Group
University of Cape Town, Cape Town, South Africa; University of California, San Francisco, San Francisco, California; Hôpital Arnaud De Villeneuve, Montpellier, France; University of Wisconsin Medical School, Madison, Wisconsin; Imperial College, London, United Kingdom; Ghent University Hospital, Ghent, Belgium; and University of Southern Denmark, Kolding Hospital, Kolding, Denmark
Correspondence and requests for reprints should be addressed to Eric D. Bateman, M.D., F.R.C.P., UCT Lung Institute, P.O. Box 34560, Groote Schuur 7937, Cape Town, South Africa. E-mail: ebateman{at}uctgsh1.uct.ac.za
For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively studied. A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving two rigorous, composite, guideline-based measures of control: totally and well-controlled asthma. Treatment was stepped-up until total control was achieved (or maximum 500 µg corticosteroid twice a day). Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with salmeterol/fluticasone than fluticasone. Total control was achieved across all strata: 520 (31%) versus 326 (19%) patients after dose escalation (p < 0.001) and 690 (41%) versus 468 (28%) at 1 year for salmeterol/fluticasone and fluticasone, respectively. Asthma became well controlled in 1,071 (63%) versus 846 (50%) after dose escalation (p < 0.001) and 1,204 (71%) versus 988 (59%) at 1 year. Control was achieved more rapidly and at a lower corticosteroid dose with salmeterol/fluticasone versus fluticasone. Across all strata, 68% and 76% of the patients receiving salmeterol/fluticasone and fluticasone, respectively, were on the highest dose at the end of treatment. Exacerbation rates (0.070.27 per patient per year) and improvement in health status were significantly better with salmeterol/fluticasone. This study confirms that the goal of guideline-derived asthma control was achieved in a majority of the patients.
Key Words: antiasthmatic agents fluticasone propionate guidelines quality of life salmeterol
This article has been cited by other articles:

|
 |

|
 |
 
M Lommatzsch, Y Lindner, A Edner, K Bratke, M Kuepper, and J C Virchow
Adverse effects of salmeterol in asthma: a neuronal perspective
Thorax,
September 1, 2009;
64(9):
763 - 769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Montuschi, G. Pagliari, and L. Fuso
Pharmacotherapy of asthma: regular treatment or on demand?
Therapeutic Advances in Respiratory Disease,
August 1, 2009;
3(4):
175 - 191.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al.
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice
Am. J. Respir. Crit. Care Med.,
July 1, 2009;
180(1):
59 - 99.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P-R. Burgel, J. de Blic, P. Chanez, C. Delacourt, P. Devillier, A. Didier, J-C. Dubus, I. Frachon, G. Garcia, M. Humbert, et al.
Update on the roles of distal airways in asthma
Eur. Respir. Rev.,
June 1, 2009;
18(112):
80 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Derom, R. Louis, C. Tiesler, R. Engelstatter, J-M. Kaufman, and G. F. Joos
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma
Eur. Respir. J.,
June 1, 2009;
33(6):
1277 - 1286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Lemanske Jr.
Asthma Therapies Revisited: What Have We Learned?
Proceedings of the ATS,
May 1, 2009;
6(3):
312 - 315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Boushey
Thomas L. Petty Aspen Lung Conference: Asthma: Insights and Expectations. Conference summary.
Proceedings of the ATS,
May 1, 2009;
6(3):
316 - 320.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Spears, I. Donnelly, L. Jolly, M. Brannigan, K. Ito, C. McSharry, J. Lafferty, R. Chaudhuri, G. Braganza, I. M. Adcock, et al.
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study
Eur. Respir. J.,
May 1, 2009;
33(5):
1010 - 1017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Drazen and P. M. O'Byrne
Risks of Long-Acting Beta-Agonists in Achieving Asthma Control
N. Engl. J. Med.,
April 16, 2009;
360(16):
1671 - 1672.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L-P. Boulet
Influence of comorbid conditions on asthma
Eur. Respir. J.,
April 1, 2009;
33(4):
897 - 906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhou, F.-m. Ding, J.-t. Lin, and K.-s. Yin
Validity of Asthma Control Test for Asthma Control Assessment in Chinese Primary Care Settings
Chest,
April 1, 2009;
135(4):
904 - 910.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H W. Kelly
Comparison of Inhaled Corticosteroids: An Update
Ann. Pharmacother.,
March 1, 2009;
43(3):
519 - 527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P J. Rees
Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma
Evid. Based Med.,
February 1, 2009;
14(1):
14 - 14.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Braman
Asthma
ACCP Pulmonary Med Brd Rev,
January 1, 2009;
25(0):
81 - 112.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. Rowe, D. C. Voaklander, D. Wang, A. Senthilselvan, T. P. Klassen, T. J. Marrie, and R. J. Rosychuk
Asthma Presentations by Adults to Emergency Departments in Alberta, Canada: A Large Population-Based Study
Chest,
January 1, 2009;
135(1):
57 - 65.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Thomas, R K McKinley, S Mellor, G Watkin, E Holloway, J Scullion, D E Shaw, A Wardlaw, D Price, and I Pavord
Breathing exercises for asthma: a randomised controlled trial
Thorax,
January 1, 2009;
64(1):
55 - 61.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Holgate, H. Bisgaard, L. Bjermer, T. Haahtela, J. Haughney, R. Horne, A. McIvor, S. Palkonen, D. B. Price, M. Thomas, et al.
The Brussels Declaration: the need for change in asthma management
Eur. Respir. J.,
December 1, 2008;
32(6):
1433 - 1442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Pelaia, T. Renda, P. Romeo, M. T. Busceti, and R. Maselli
Review: Omalizumab in the treatment of severe asthma: efficacy and current problems
Therapeutic Advances in Respiratory Disease,
December 1, 2008;
2(6):
409 - 421.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. O'Byrne, I. P. Naya, A. Kallen, D. S. Postma, and P. J. Barnes
Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled {beta}2-Agonists in Achieving Asthma Control
Chest,
December 1, 2008;
134(6):
1192 - 1199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Campbell, L. Borish, T. Haselkorn, L. Rasouliyan, J. H. Lee, S. E. Wenzel, S. D. Sullivan, and on behalf of the TENOR Study Group
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Eur. Respir. J.,
November 1, 2008;
32(5):
1237 - 1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Nkoy, B. A. Fassl, T. D. Simon, B. L. Stone, R. Srivastava, P. H. Gesteland, G. M. Fletcher, and C. G. Maloney
Quality of Care for Children Hospitalized With Asthma
Pediatrics,
November 1, 2008;
122(5):
1055 - 1063.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lindmark
Review: Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma
Therapeutic Advances in Respiratory Disease,
October 1, 2008;
2(5):
279 - 299.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Taylor, E. D. Bateman, L-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, J. C. de Jongste, et al.
A new perspective on concepts of asthma severity and control
Eur. Respir. J.,
September 1, 2008;
32(3):
545 - 554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. LANG
New asthma guidelines emphasize control, regular monitoring
Cleveland Clinic Journal of Medicine,
September 1, 2008;
75(9):
641 - 653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P Bhavsar, M Hew, N Khorasani, A Torrego, P J Barnes, I Adcock, and K F Chung
Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma
Thorax,
September 1, 2008;
63(9):
784 - 790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Thorsteinsdottir, G. W. Volcheck, B. E. Madsen, A. M. Patel, J. T. C. Li, and K. G. Lim
The ABCs of Asthma Control
Mayo Clin. Proc.,
July 1, 2008;
83(7):
814 - 820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, H. Ortega, and S. Yancey
Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events
Ann Intern Med,
July 1, 2008;
149(1):
33 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Greening, D. Stempel, E. D. Bateman, and J. C. Virchow
Managing asthma patients: which outcomes matter?
Eur. Respir. Rev.,
June 1, 2008;
17(108):
53 - 61.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Sears, L-P. Boulet, M. Laviolette, J. M. Fitzgerald, T. R. Bai, A. Kaplan, N. Smiljanic-Georgijev, and J. S-M. Lee
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma
Eur. Respir. J.,
May 1, 2008;
31(5):
982 - 989.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Hanania
Targeting Airway Inflammation in Asthma: Current and Future Therapies
Chest,
April 1, 2008;
133(4):
989 - 998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Levy
Guideline-defined asthma control: a challenge for primary care
Eur. Respir. J.,
February 1, 2008;
31(2):
229 - 231.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Chapman, L. P. Boulet, R. M. Rea, and E. Franssen
Suboptimal asthma control: prevalence, detection and consequences in general practice
Eur. Respir. J.,
February 1, 2008;
31(2):
320 - 325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al.
Global strategy for asthma management and prevention: GINA executive summary
Eur. Respir. J.,
January 1, 2008;
31(1):
143 - 178.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. van den Nieuwenhof, T. Schermer, M. Heins, J. Grootens, P. Eysink, B. Bottema, C. van Weel, and P. Bindels
Tracing Uncontrolled Asthma in Family Practice Using a Mailed Asthma Control Questionnaire
Ann. Fam. Med,
January 1, 2008;
6(suppl_1):
S16 - S22.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cazzola and M. G. Matera
Review: Safety of long-acting {beta}2 -agonists in the treatment of asthma
Therapeutic Advances in Respiratory Disease,
October 1, 2007;
1(1):
35 - 46.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Osborne, K. L. Pedula, M. O'Hollaren, K. M. Ettinger, T. Stibolt, A. S. Buist, and W. M. Vollmer
Assessing Future Need for Acute Care in Adult Asthmatics: The Profile of Asthma Risk Study: A Prospective Health Maintenance Organization-Based Study
Chest,
October 1, 2007;
132(4):
1151 - 1161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Holgate
Anti-IgE: changing lives in clinical practice?
Eur. Respir. Rev.,
September 1, 2007;
16(104):
59 - 60.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Partridge
Examining the unmet need in adults with severe asthma
Eur. Respir. Rev.,
September 1, 2007;
16(104):
67 - 72.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hendeles and C. A Sorkness
Anti-Immunoglobulin E Therapy with Omalizumab for Asthma
Ann. Pharmacother.,
September 1, 2007;
41(9):
1397 - 1410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C. Beier, T. Kallinich, and E. Hamelmann
T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease
Eur. Respir. J.,
August 1, 2007;
30(2):
383 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. van der Meer, H. F. van Stel, S. B. Detmar, W. Otten, P. J. Sterk, and J. K. Sont
Internet-Based Self-Management Offers an Opportunity To Achieve Better Asthma Control in Adolescents
Chest,
July 1, 2007;
132(1):
112 - 119.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The American Lung Association Asthma Clinical Rese
Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma
N. Engl. J. Med.,
May 17, 2007;
356(20):
2027 - 2039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Wechsler, J.-A. O. Shepard, and E. J. Mark
Case 15-2007 -- A 20-Year-Old Woman with Asthma and Cardiorespiratory Arrest
N. Engl. J. Med.,
May 17, 2007;
356(20):
2083 - 2091.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Bell and R. A. McIvor
The SMART study
Can Fam Physician,
April 1, 2007;
53(4):
687 - 688.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Schermer, J. Albers, H. Verblackt, R. Costongs, and P Westers
Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD
Fam. Pract.,
April 1, 2007;
24(2):
181 - 188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barnes
Scientific rationale for using a single inhaler for asthma control
Eur. Respir. J.,
March 1, 2007;
29(3):
587 - 595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Boot, S. de Haas, S. Tarasevych, C. Roy, L. Wang, D. Amin, J. Cohen, P. J. Sterk, B. Miller, A. Paccaly, et al.
Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma
Am. J. Respir. Crit. Care Med.,
March 1, 2007;
175(5):
450 - 457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Moore, E. E. Millman, V. Godines, N. A. Hanania, T. M. Tran, H. Peng, B. F. Dickey, B. J. Knoll, and R. B. Clark
Salmeterol Stimulation Dissociates beta2-Adrenergic Receptor Phosphorylation and Internalization
Am. J. Respir. Cell Mol. Biol.,
February 1, 2007;
36(2):
254 - 261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The American Lung Association Asthma Clinical Rese
Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma
Am. J. Respir. Crit. Care Med.,
February 1, 2007;
175(3):
235 - 242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Bateman, J. Bousquet, M. L. Keech, W. W. Busse, T. J. H. Clark, S. E. Pedersen, and on behalf of the GOAL Investigators Group
The correlation between asthma control and health status: the GOAL study
Eur. Respir. J.,
January 1, 2007;
29(1):
56 - 62.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Erickson, P. L. Splett, S. S. Mullett, C. Jensen, and S. B. Belseth
The Healthy Learner Model for Student Chronic Condition Management--Part II: The Asthma Initiative
The Journal of School Nursing,
December 1, 2006;
22(6):
319 - 329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. v. d. Nieuwenhof, T. Schermer, P. Eysink, E. Halet, C. van Weel, P. Bindels, and B. Bottema
Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study
Fam. Pract.,
December 1, 2006;
23(6):
674 - 681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ernst, A. McIvor, F. M. Ducharme, L.-P. Boulet, M. FitzGerald, K. R. Chapman, T. Bai, and for the Canadian Asthma Guideline Group
Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids.
Ann Intern Med,
November 7, 2006;
145(9):
692 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. S. Nelson and P. M. Dorinsky
Safety of long-acting beta-agonists.
Ann Intern Med,
November 7, 2006;
145(9):
706 - 706.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Glassroth
Use of long-acting beta-agonists and inhaled corticosteroids.
Ann Intern Med,
November 7, 2006;
145(9):
710 - 710.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J M FitzGerald and P G Gibson
Asthma exacerbations {middle dot} 4: Prevention.
Thorax,
November 1, 2006;
61(11):
992 - 999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Lavoie, S. L. Bacon, S. Barone, A. Cartier, B. Ditto, and M. Labrecque
What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both?
Chest,
October 1, 2006;
130(4):
1039 - 1047.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L van der Merwe, A de Klerk, M Kidd, P G Bardin, and E M van Schalkwyk
Case-control study of severe life threatening asthma (SLTA) in a developing community
Thorax,
September 1, 2006;
61(9):
756 - 760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Langan, K. S. Thomas, and H. C. Williams
What is meant by a "flare" in atopic dermatitis?: a systematic review and proposal.
Arch Dermatol,
September 1, 2006;
142(9):
1190 - 1196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bell and R. A. McIvor
SMART therapy.
Can. Med. Assoc. J.,
August 1, 2006;
175(3):
276 - 277.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Reddel and D. J. Barnes
Pharmacological strategies for self-management of asthma exacerbations.
Eur. Respir. J.,
July 1, 2006;
28(1):
182 - 199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schatz, R. S. Zeiger, W. M. Vollmer, D. Mosen, G. Mendoza, A. J. Apter, T. B. Stibolt, A. Leong, M. S. Johnson, and E. F. Cook
The Controller-to-Total Asthma Medication Ratio Is Associated With Patient-Centered As Well As Utilization Outcomes.
Chest,
July 1, 2006;
130(1):
43 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Glassroth
The Role of Long-Acting {beta}-Agonists in the Management of Asthma: Analysis, Meta-Analysis, and More Analysis
Ann Intern Med,
June 20, 2006;
144(12):
936 - 937.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Bateman
The economic burden of uncontrolled asthma across Europe and the Asia-Pacific region: can we afford to not control asthma?
Eur. Respir. Rev.,
June 1, 2006;
15(98):
1 - 3.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. W. Lai, Y-Y. Kim, S-H. Kuo, M. Spencer, A. E. Williams, and on behalf of the Asthma Insights and Reality in As
Cost of asthma in the Asia-Pacific region
Eur. Respir. Rev.,
June 1, 2006;
15(98):
10 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. W. Lai, S-H. Kuo, T. de Guia, A. Lloyd, A. E. Williams, and M. D. Spencer
Asthma control and its direct healthcare costs: findings using a derived Asthma Control TestTM score in eight Asia-Pacific areas
Eur. Respir. Rev.,
June 1, 2006;
15(98):
24 - 29.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Gelb, C. Flynn Taylor, C. M. Shinar, C. Gutierrez, and N. Zamel
Role of Spirometry and Exhaled Nitric Oxide To Predict Exacerbations in Treated Asthmatics
Chest,
June 1, 2006;
129(6):
1492 - 1499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Rees
Asthma control in adults.
BMJ,
April 1, 2006;
332(7544):
767 - 771.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Mintz, G. T. O'Connor, and F. D. Martinez
Safety of long-acting beta-agonists.
N. Engl. J. Med.,
March 16, 2006;
354(11):
1206 - 1208.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Marcus
Incorporating Anti-IgE (Omalizumab) Therapy Into Pulmonary Medicine Practice: Practice Management Implications.
Chest,
February 1, 2006;
129(2):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. O'Byrne and E. Adelroth
{beta}2 Deja Vu
Chest,
January 1, 2006;
129(1):
3 - 5.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Barnes, J. C. Virchow, J. Sanchis, T. Welte, and S. Pedersen
Asthma management: important issues
Eur. Respir. Rev.,
December 1, 2005;
14(97):
147 - 151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Eur. Respir. J.,
November 1, 2005;
26(5):
819 - 828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. P. Currie, D. K. C. Lee, and P. Srivastava
Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?
Chest,
October 1, 2005;
128(4):
2954 - 2962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. O'Byrne
Daily Inhaled Corticosteroid Treatment Should Be Prescribed for Mild Persistent Asthma
Am. J. Respir. Crit. Care Med.,
August 15, 2005;
172(4):
410 - 412.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P J. Rees
Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma
Evid. Based Med.,
August 1, 2005;
10(4):
116 - 116.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Bateman
GOAL--Asthma Control, but at What Cost?
Am. J. Respir. Crit. Care Med.,
July 15, 2005;
172(2):
255 - 256.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. G. Todd
GOAL--Asthma Control, but at What Cost?
Am. J. Respir. Crit. Care Med.,
July 15, 2005;
172(2):
254 - 255.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. B. Marks
Identifying asthma in population studies: from single entity to a multi-component approach
Eur. Respir. J.,
July 1, 2005;
26(1):
3 - 5.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gaga, N. Papageorgiou, E. Zervas, D. Gioulekas, and S. Konstantopoulos
Control of Asthma Under Specialist Care: Is It Achieved?
Chest,
July 1, 2005;
128(1):
78 - 84.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Wechsler and E. Israel
How Pharmacogenomics Will Play a Role in the Management of Asthma
Am. J. Respir. Crit. Care Med.,
July 1, 2005;
172(1):
12 - 18.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Smith, J. O. Cowan, K. P. Brassett, G. P. Herbison, and D. R. Taylor
Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma
N. Engl. J. Med.,
May 26, 2005;
352(21):
2163 - 2173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Fardon and B. J. Lipworth
An Own GOAL or a Real Breakthrough?
Am. J. Respir. Crit. Care Med.,
May 1, 2005;
171(9):
1060 - 1060.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Bateman and for the GOAL Study Steering Committee
The GOAL Study Designed to Favor a Long-acting {beta}2-Agonist?
Am. J. Respir. Crit. Care Med.,
May 1, 2005;
171(9):
1061 - 1061.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. P. Currie and D. K. C. Lee
The GOAL Study Designed to Favor a Long-acting {beta}2-Agonist?
Am. J. Respir. Crit. Care Med.,
May 1, 2005;
171(9):
1060 - 1061.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fabbri, S. P. Peters, I. Pavord, S. E. Wenzel, S. C. Lazarus, W. MacNee, F. Lemaire, and E. Abraham
Allergic Rhinitis, Asthma, Airway Biology, and Chronic Obstructive Pulmonary Disease in AJRCCM in 2004
Am. J. Respir. Crit. Care Med.,
April 1, 2005;
171(7):
686 - 698.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. P Currie, G. S Devereux, D. K C Lee, and J. G Ayres
Recent developments in asthma management
BMJ,
March 12, 2005;
330(7491):
585 - 589.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Gibson
Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers
Eur. Respir. J.,
March 1, 2005;
25(3):
397 - 399.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barnes
A Single Inhaler for Asthma?
Am. J. Respir. Crit. Care Med.,
January 15, 2005;
171(2):
95 - 96.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.K. Reddel
Goals of asthma treatment: how high should we go?
Eur. Respir. J.,
November 1, 2004;
24(5):
715 - 717.
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 American Thoracic Society
|
|
|